CeleBrate results presented at AHA Scientific Sessions, published in NEJM Evidence
Pivotal Phase 3 study meets primary efficacy and safety endpoints
Results of the pivotal Phase 3 multinational CeleBrate clinical trial were presented on Nov. 10 during a late-breaking session at the American Heart Association’s Annual Scientific Sessions in New Orleans. The results were published simultaneously in The New England Journal of Medicine Evidence.
CeleBrate was a prospective, blinded, randomized, placebo-controlled trial that assessed the efficacy and safety of a single subcutaneous injection of the investigational antiplatelet drug zalunfiban* in STEMI patients in the pre-hospital setting. It enrolled 2,467 patients at 45 sites in the United States, Canada, Mexico and Europe.
*Zalunfiban is an investigational agent; it has not been approved for any use and its safety and efficacy have not been established.
For a copyrighted reprint of the article, email contact@celecor.com.
Expert commentary
C. Michael Gibson, M.D.
Christopher B. Granger, M.D.
Member, Duke Clinical Research Institute
Barry S. Coller, M.D.
David Rockefeller Professor, head of the Allen and Frances Adler Laboratory of Blood and Vascular Biology, VP for medical affairs and physician-in-chief,
The Rockefeller University
